58
Participants
Start Date
February 10, 2021
Primary Completion Date
November 4, 2022
Study Completion Date
November 4, 2022
V114
15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
CHA Bundang Medical Center CHA University ( Site 0020), Seongnam-si
Hallym University Sacred Heart Hospital ( Site 0011), Anyang-si
Korea University Ansan Hospital ( Site 0006), Ansan-si
Hallym University Dongtan Sacred Heart Hospital ( Site 0013), Hwaseong-si
The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 0012), Incheon
Gachon University Gil Medical Center ( Site 0019), Incheon
Inha University Hospital ( Site 0001), Incheon
Kyungpook National University Hospital ( Site 0014), Daegu
Pusan National University Yangsan Hospital ( Site 0009), Yangsan
Changwon Fatima Hospital ( Site 0015), Changwon
Jeonbuk National University Hospital ( Site 0008), Jeonju
Korea Cancer Center Hospital ( Site 0017), Seoul
Nowon Eulji Medical Center, Eulji University ( Site 0005), Seoul
Severance Hospital Yonsei University Health System ( Site 0002), Seoul
Samsung Medical Center ( Site 0007), Seoul
The Catholic University of Korea ( Site 0003), Seoul
Chung-Ang University Hospital ( Site 0016), Seoul
Ewha Womans University Seoul Hospital ( Site 0010), Seoul
Korea University Guro Hospital ( Site 0021), Seoul
Merck Sharp & Dohme LLC
INDUSTRY